Periodontal disease has an astounding impact on millions of Americans, yet many remain unaware that they may be affected. That makes it crucial for periodontitis patients to prioritize in-office hygiene appointments for effective disease monitoring and management.
A Targeted Approach to Perio Care
ARESTIN (minocycline HCl) microspheres, 1 mg is indicated as an adjunct to scaling and root planing (SRP) for reduction of pocket depth in adult periodontitis patients. It may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP. ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines.
In a pivotal study, the primary endpoint demonstrated statistically significant pocket depth reduction at 9 months. ARESTIN also helps prevent bacteria from growing, allowing the gums time to heal while reaching areas of the pocket in a way that SRP alone may not.
The site-specific placement of ARESTIN is easy and does not require needles or anesthesia. In most cases, application takes just seconds after SRP is performed. ARESTIN is provided in a ready-to-use, unit-dose cartridge and is administered via a sterilizable stainless-steel, spring-loaded cartridge handle mechanism. Once applied, ARESTIN remains active in the pocket for at least 14 days, with sustained pocket depth reduction continuing across a 9-month period.
Backed by Clinical Studies
Research suggests that SRP alone is only effective for 39% of adult periodontitis patients.1 When combined with ARESTIN as part of a routine periodontal disease management program, however, studies show that patients experience a nearly 20% greater reduction in pocket depth compared to those who only receive SRP. Additionally, patients with deeper pockets (6 mm or more) are 3 times more likely to see a reduction to less than 5 mm after receiving both treatments.2
References
1. Van der Weijden GAF, Dekkers GJ, Slot DE. Success of non-surgical periodontal therapy in adult periodontitis patients: A retrospective analysis. Int J Dent Hyg. 2019;309-317. doi: 10.1111/idh.12399
2. Williams RC, Paquette DW, Offenbacher S, et al. Treatment of periodontitis by local administration of minocycline microspheres: A controlled trial. J Periodontol. 2001;72(11):1535-1544. doi: 10.1902/jop.2001.72.11.1535FOR
INDICATION
ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) for reduction of pocket depth in adult periodontitis patients. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines.
WARNINGS AND PRECAUTIONS
• ARESTIN should not be used in children, pregnant or nursing women as the use of tetracycline drugs during tooth development may cause permanent discoloration of the teeth.
• Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the fi rst evidence of skin erythema.
• Hypersensitivity reactions and hypersensitivity syndrome included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia. Post- marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline.
• Tetracyclines, including oral minocycline, have been associated with development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, discontinue use of ARESTIN.
• The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
• The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.
ADVERSE REACTIONS
The most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.
To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information on next page and www.arestinprofessional.com
